Albert Farrugia

List of Publications by Citations

147 papers	1,607 citations	20 h-index	34 g-index
163 ext. papers	1,823 ext. citations	4.2 avg, IF	5.17 L-index

#	Paper	IF	Citations
147	Albumin usage in clinical medicine: tradition or therapeutic?. *Transfusion Medicine Reviews*, **2010**, 24, 53-63	7.4	126
146	Estimation of the latent therapeutic demand for albumin in the USA: a focus on three indications. *Critical Care*, **2015**, 19, P354	10.8	78
145	Payment, compensation and replacement--the ethics and motivation of blood and plasma donation. *Vox Sanguinis*, **2010**, 99, 202-11	3.1	68
144	A study of reported factor VIII use around the world. *Haemophilia*, **2010**, 16, 33-46	3.3	66
143	Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant. *Vox Sanguinis*, **1987**, 52, 257-64	3.1	61
142	Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. *Transfusion*, **2007**, 47, 529-39	2.9	60
141	External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. *PLoS Medicine*, **2012**, 9, e1001309	11.6	56
140	The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. *American Journal of Transplantation*, **2007**, 7, 2723-6	8.7	55
139	Economic considerations on transfusion medicine and patient blood management. *Baillieres Best Practice and Research in Clinical Anaesthesiology*, **2013**, 27, 59-68	4	52
138	Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. *Haemophilia*, **2013**, 19, e228-38	3.3	40
137	The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy. *Vox Sanguinis*, **2020**, 115, 603-605	3.1	37
136	Plasma for fractionation: safety and quality issues. *Haemophilia*, **2004**, 10, 334-40	3.3	34
135	Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. *Journal of Clinical Immunology*, **2014**, 34, 233-44	5.7	32
134	Plasma fractionation issues. *Biologicals*, **2009**, 37, 88-93	1.8	31
133	Intravenous immunoglobulin: regulatory perspectives on use and supply. *Transfusion Medicine*, **2001**, 11, 63-74	1.3	30
132	Plasma protein therapies: current and future perspectives. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 243-58	4.2	28
131	The mantra of blood safety: time for a new tune?. *Vox Sanguinis*, **2004**, 86, 1-7	3.1	22

130	Evolving perspectives in product safety for haemophilia. *Haemophilia*, **2002**, 8, 236-43	3.3	22
129	Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives. *Haemophilia*, **2002**, 8, 230-5	3.3	21
128	Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells. *Vox Sanguinis*, **1992**, 63, 31-8	3.1	21
127	Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. *Transfusion*, **2015**, 55, 1067-74	2.9	19
126	A study of reported factor IX use around the world. *Haemophilia*, **2011**, 17, 446-55	3.3	19
125	The regulatory pendulum in transfusion medicine. *Transfusion Medicine Reviews*, **2002**, 16, 273-82	7.4	19
124	Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty. *Vox Sanguinis*, **2005**, 89, 186-92	3.1	19
123	Haemophilia 2002: emerging risks of treatment. *Haemophilia*, **2002**, 8, 221-9	3.3	18
122	Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy. *Frontiers in Immunology*, **2014**, 5, 665	8.4	17
121	Health technology assessment and haemophilia. *Haemophilia*, **2012**, 18, 152-7	3.3	17
120	Relative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies. *Current Drug Safety*, **2013**, 8, 236-45	1.4	17
119	When do tissues and cells become products? Regulatory oversight of emerging biological therapies. *Cell and Tissue Banking*, **2006**, 7, 325-35	2.2	17
118	Donation procedure, fibrinopeptide A, and factor VIII. *Vox Sanguinis*, **1984**, 46, 55-7	3.1	17
117	Safety and supply of haemophilia products: worldwide perspectives. *Haemophilia*, **2004**, 10, 327-33	3.3	16
116	Globalisation and blood safety. *Blood Reviews*, **2009**, 23, 123-8	11.1	15
115	Falsification or paradigm shift? Toward a revision of the common sense of transfusion. *Transfusion*, **2011**, 51, 216-24	2.9	13
114	Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations. *Biologicals*, **1997**, 25, 87-92	1.8	13
113	Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay. *Biologicals*, **1998**, 26, 155-66	1.8	13

112	Comparing objective and self-reported measures of adherence in haemophilia. *Haemophilia*, **2019**, 25, 821-830	3.3	12
111	Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials. *Reviews on Recent Clinical Trials*, **2014**, 9, 21-30	1.2	12
110	Safety of plasma volume expanders. *Journal of Clinical Pharmacology*, **2011**, 51, 292-300	2.9	12
109	Stabilization of von Willebrand factor in banked blood by leucocyte depletion. *Transfusion Medicine*, **1993**, 3, 51-7	1.3	12
108	Plasma-derived medicines: access and usage issues. *Blood Transfusion*, **2012**, 10, 273-8	3.6	12
107	Some reflections on the Code of Ethics of the International Society of Blood Transfusion. *Blood Transfusion*, **2015**, 13, 551-8	3.6	12
106	Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003. *Transfusion and Apheresis Science*, **2007**, 37, 233-40	2.4	11
105	Relative efficiency of leucocyte removal procedures for the production of leucocyte-poor red cell concentrates assessed by flow cytometry. *Vox Sanguinis*, **1994**, 66, 153-60	3.1	11
104	Improved in-vitro quality of platelet concentrates stored in a dextrose-free synthetic medium. *Transfusion Medicine*, **1991**, 1, 31-8	1.3	11
103	Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality. *Journal of Clinical Pathology*, **1985**, 38, 433-7	3.9	11
102	Is self-sufficiency in haemotherapies a practical or necessary goal?. *Blood Transfusion*, **2013**, 11, 183-92	3.6	11
101	Stem cell and cellular therapy developments. *Biologicals*, **2009**, 37, 103-7	1.8	10
100	Safety Issues of Plasma-Derived Products for Treatment of Inherited Bleeding Disorders. *Seminars in Thrombosis and Hemostasis*, **2016**, 42, 583-8	5.3	10
99	The dynamics of contract plasma fractionation. *Biologicals*, **2017**, 46, 159-167	1.8	9
98	Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study. *Journal of Clinical Immunology*, **2019**, 39, 159-170	5.7	9
97	The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness. *HEC Forum*, **2015**, 27, 417-29	1.1	9
96	Platelet size analysis in the quality assurance of platelet concentrates for transfusion. *International Journal of Laboratory Hematology*, **1995**, 17, 51-5		9
95	Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 1022-3	15.4	8

94	Use of Plasma with High Levels of Ionised Calcium in the Production of Model Scale Goagulation Factor Concentrates. *Thrombosis and Haemostasis*, **1990**, 64, 374-378	7	8
93	The Boldt affair: correcting a collective failure. *Anesthesia and Analgesia*, **2012**, 115, 207	3.9	7
92	Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia. *Transplant International*, **2008**, 21, 936-41	3	7
91	Emerging and receding risks of therapeutic regimens for haemophilia. *Haemophilia*, **2004**, 10 Suppl 4, 47-54	3.3	7
90	Product delivery in the developing world: options, opportunities and threats. *Haemophilia*, **2004**, 10 Suppl 4, 77-82	3.3	7
89	Modulation of fibrinogen content in cryoprecipitate by temperature manipulation during plasma processing. *Transfusion*, **1992**, 32, 755-9	2.9	7
88	Platelet concentrates for transfusion-metabolic and storage aspects. *Platelets*, **1994**, 5, 177-85	3.6	7
87	von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity). *Thrombosis Research*, **1992**, 65, 389-99	8.2	7
86	Microtitre plate measurement of platelet response to hypotonic stress. *Journal of Clinical Pathology*, **1989**, 42, 1298-301	3.9	7
85	Effects of plasma collection systems and processing parameters on the quality of factor IX concentrate. *Vox Sanguinis*, **1989**, 57, 4-9	3.1	7
84	Joint WFH-ISTH session: issues in clinical trial design. *Haemophilia*, **2014**, 20 Suppl 4, 137-44	3.3	6
83	Toward a patient-based paradigm for blood transfusion. *Journal of Blood Medicine*, **2014**, 5, 5-13	2.3	6
82	Potency assessment of the new generation of coagulation factor concentrates Time for a new paradigm?. *Thrombosis and Haemostasis*, **2003**, 90, 968-970	7	6
81	Cryopreservation of red blood cells: effect of freezing on red cell quality and residual lymphocyte immunogenicity. *Journal of Clinical Pathology*, **1993**, 46, 742-5	3.9	6
80	Factor VIII/von Willebrand factor levels in plasma frozen to-30 degrees C in air or halogenated hydrocarbons. *Thrombosis Research*, **1992**, 68, 97-102	8.2	6
79	A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. *Thrombosis and Haemostasis*, **1984**, 51, 110-4	7	6
78	The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. *International Journal of Infectious Diseases*, **2021**, 102, 244-246	10.5	6
77	Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics. *Journal of Blood Medicine*, **2015**, 6, 185-95	2.3	5

76	Studies on the Procurement of Coagulation Factor VIII: Selective Precipitation of Factor VIII with Hydrophilic Polymers. *Thrombosis and Haemostasis*, **1984**, 51, 338-342	7	5
75	Iron and blood donation- an under-recognised safety issue. *Developments in Biologicals*, **2007**, 127, 137-46		5
74	Convalescent plasma - this is no time for competition. *Transfusion*, **2020**, 60, 1644-1646	2.9	4
73	Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies. *Transfusion*, **2015**, 55, 224-6	2.9	4
72	Concerning Chapter 5 - Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399-407. *Transfusion Medicine and Hemotherapy*, **2010**, 37, 98-99	4.2	4
71	Challenges in the evaluation of safety and efficacy of human tissue and cell based products. *ANZ Journal of Surgery*, **2006**, 76, 843-9	1	4
70	Hepatitis C virus transmission by intravenous immunoglobulin. *Lancet, The*, **1995**, 346, 373-375	40	4
69	The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative. *Blood Transfusion*, **2019**, 17, 449-458	3.6	4
68	Reply to Flanagan "The Code of Ethics of the International Society of Blood Transfusion" [Blood Transfus 2015; 13: 537-8]. *Blood Transfusion*, **2017**, 15, 286-288	3.6	4
67	Assessing options for treating haemophilia with inhibitors. *Haemophilia*, **2015**, 21, 307-9	3.3	3
66	Are we optimising outcomes in Australia's framework for the supply of plasma-derived medicines?. *Medical Journal of Australia*, **2016**, 205, 336	4	3
65	Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities. *Transfusion Clinique Et Biologique*, **2020**, 27, 167-168	1.9	3
64	HIV safety in sub-Saharan Africa. *Vox Sanguinis*, **2011**, 100, 434-5; author reply 436-7	3.1	3
63	Risk of parvovirus infection by immunoglobulin. *British Journal of Haematology*, **2003**, 121, 955-6; author reply 956	4.5	3
62	Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. *Blood Transfusion*, **2018**, 16, 525-534	3.6	3
61	Herd immunity and primary immune deficiencies. *Vaccine*, **2019**, 37, 3942-3943	4.1	3
60	Perspectives on haemophilia access in Brazil?. *Haemophilia*, **2018**, 24, e255-e256	3.3	2
59	Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. *Haemophilia*, **2019**, 25, e364-e367	3.3	2

58	Errors and Omissions: Donor Compensation Policies and Richard Titmuss. *HEC Forum*, **2015**, 27, 319-30	1.1	2
57	Potency measurement of factor VIII in recombinant concentrates. *Haemophilia*, **1996**, 2, 153-9	3.3	2
56	Laboratory practice and studies of bovine spongiform encephalopathy. *Lancet, The*, **2002**, 359, 1067-8	40	2
55	Components prepared from blood collected into dextrose-free anticoagulant. In vitro properties of platelets suspended in plasma and in dextrose-free synthetic medium. *Transfusion Science*, **1993**, 14, 409-416		2
54	Storage of platelet concentrates harvested from blood collected into dextrose-free preservative without agitation. *Transfusion Medicine*, **1993**, 3, 223-228	1.3	2
53	Studies on the Procurement of Blood Coagulation Factor VIII in vitro Studies on Blood Components Prepared in Half-Strength Citrate Anticoagulant. *Vox Sanguinis*, **1987**, 52, 257-264	3.1	2
52	Where now for transfusion: the evolution of a paradigm and its logical progression. *Transfusion*, **2016**, 56 Suppl 2, S224-32	2.9	2
51	ABO-incompatible convalescent plasma transfusion: Yes, you can. *Transfusion Medicine*, **2021**, 31, 215-216	1.3	2
50	Usual and unusual mutations in a cohort of Belgian patients with hemophilia B. *Thrombosis Research*, **2017**, 149, 25-28	8.2	1
49	The multiple benefits of sport in haemophilia. *Haemophilia*, **2018**, 24, 341-343	3.3	1
48	Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. *Expert Review of Hematology*, **2019**, 12, 883-892	2.8	1
47	Letter to the editor--Response to "How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems?" F. Rossi, R. Perry, J. de Wit,T. Evers & G. Folli, Vox Sanguinis DOI: 10.1111/j.1423-0410.2011.01495.x. *Vox Sanguinis*, **2012**, 102, 269-70	3.1	1
46	Response to Laub et´al., "Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations"Vox Sanguinis (2010) 99, 220-231. *Vox Sanguinis*, **2011**, 100, 438; author reply 439	3.1	1
45	Trialing plasma protein therapies for rare disorders: Thinking outside the box. *Pharmaceuticals Policy and Law*, **2009**, 11, 345-352		1
44	Remuneration of blood donors: let us compare apples with apples. *Vox Sanguinis*, **2009**, 96, 349; author reply 350-1	3.1	1
43	Response to Volkow P et al. - Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities - International Journal of Drug Policy 20 (2009) 409-412. *International Journal of Drug Policy*, **2010**, 21, 343-4; discussion 345-6	5.5	1
42	Regulatory oversight of cellular therapies. *ISBT Science Series*, **2007**, 2, 141-146	1.1	1
41	Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives. *Seminars in Hematology*, **2006**, 43, S64-9	4	1

40	Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada. *Transfusion and Apheresis Science*, **2006**, 35, 151-172	2.4	1
39	Globalization and blood safety. *ISBT Science Series*, **2006**, 1, 25-32	1.1	1
38	Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates. *Thrombosis and Haemostasis*, **1990**, 64, 374-8	7	1
37	Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al. *Blood Transfusion*, **2019**, 17, 85	3.6	1
36	Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 132-133	4.2	1
35	Some characteristics of blood shed into the Solcotrans postoperative orthopaedic drainage/reinfusion system. *Medical Journal of Australia*, **1992**, 157, 95-6	4	1
34	Supporting Garraud´-´and protecting transfusion. *Transfusion Clinique Et Biologique*, **2020**, 27, 170-171	1.9	1
33	Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States. *Vox Sanguinis*, **2021**,	3.1	1
32	Comparative analysis of marketed factor VIII products: comment. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 232-233	15.4	1
31	Improving access to haemophilia therapies-Beyond humanitarian aid. *Haemophilia*, **2018**, 24, e430-e432	3.3	1
30	Flow-cytometric method for the quantitation of the Fc function of intravenous immunoglobulin preparations. *Vox Sanguinis*, **2000**, 78, 185-93	3.1	1
29	Assessing causality in the transmission of viruses by blood products. *Transfusion*, **2012**, 52, 1598; author reply 1598-9	2.9	0
28	The discovery of cryoprecipitate as a modality for hemophilia A: Augmenting the allocation of credit. *Transfusion*, **2021**, 61, 2517-2518	2.9	0
27	Storage of cryoprecipitate: Role of blood storage. *Transfusion*, **2021**, 61, 2800-2801	2.9	0
26	Time to review the way we estimate access to haemophilia concentrates worldwide. *Haemophilia*, **2017**, 23, e235-e237	3.3	
25	Innovation in Hemophilia Therapies - "And Miles to Go, before [We] Sleep". *Seminars in Thrombosis and Hemostasis*, **2017**, 43, 105-106	5.3	
24	Concerns regarding clinical trials in haemophilia-Augmenting Iorio© "Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development" Haemophilia (2017), 1-3 https://doi.org/10.1111/hae.13176. *Haemophilia*, **2017**, 23, e475-e476	3.3	
23	Albumin: Therapeutic Role in the Current Era **2014**, 395-404		

22	Products Used to Treat Hemophilia: Regulation **2014**, 185-191	
21	Hemophilia treatment and the AIDS tragedy: closing the circle. *Transfusion*, **2014**, 54, 1199	2.9
20	Albumin from rice: why and wherefore?. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E775	11.5
19	Conditions for plasma processing. *Transfusion*, **2011**, 51, 1875-6; author reply 1876	2.9
18	A Regulatory System for Cell and Tissue Therapies: Proposed Approach in Australia **2009**, 37-48	
17	Products used to Treat Hemophilia: Regulation **2010**, 170-175	
16	Trends in prevalence of viral infections in Australian musculoskeletal tissue donors and projections of incidence and residual risk, 1993-2004. *Transplantation*, **2008**, 86, 746-8	1.8
15	Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?. *Haemophilia*, **2004**, 10 Suppl 4, 83-7	3.3
14	In vitro properties of additive suspended red cells collected into a dextrose-free anticoagulant. *Transfusion Science*, **1994**, 15, 73-78	
13	Red Cell and Platelet Concentrates from Blood Collected into Half- Strength Citrate Anticoagulant: Improved Maintenance of Red Cell 2,3-Diphosphoglycerate in Half-Citrate Red Cells. *Vox Sanguinis*, **1992**, 63, 31-38	3.1
12	A microtitre plate test for assessment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate. *Thrombosis Research*, **1989**, 53, 191-6	8.2
11	Viral safety of coagulation factor concentrates. *Transfusion Science*, **1991**, 12, 161-162	
10	Fresh frozen plasma: Beyond coagulation factor content.. *Transfusion Medicine*, **2022**,	1.3
9	Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII. *Australasian Biotechnology*, **1993**, 3, 16-20	
8	Cost of pathogen reduction for platelets: reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9. *Blood Transfusion*, **2019**, 17, 84	3.6
7	Concerns regarding immunoglobulins. *Transfusion and Apheresis Science*, **2020**, 59, 102693	2.4
6	The interphase between immunoglobulin, the plasma industry and the public health, managing a finite resource. *Transfusion Clinique Et Biologique*, **2021**, 28, 86-88	1.9
5	Factor VIII manufactured from plasma the ups and downs, and the up again: a personal journey Part 1: history of the development of plasma-derived factor VIII therapies. *Annals of Blood* , **2018**, 3, 17-17	0.6

4	Factor VIII manufactured from plasma□he ups and downs, and the up again: a personal journey□art 2: aspects of factor VIII manufacture from plasma. *Annals of Blood*, **2018**, 3, 20-20	0.6
3	Appropriately specifying the quality of plasma for fractionation. *Vox Sanguinis*, **2021**,	3.1
2	The safety of plasma-derived haemophilia factor concentrates - comments on "Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates" Nunes Valen□ I et´al. (2021). Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates. Haemophilia. https://doi.org/10.1111/hae.14382. *Haemophilia*, **2021**, 27, e760-e761	3.3
1	Albumin in plasma exchange - A rethink is required. *Transfusion and Apheresis Science*, **2021**, 60, 103175	2.4